Please assess the completion status of the following clinical trial:

Trial Title: Validation Durability Adenosine Effect in Verification Pulmonary Vein Isolation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing atrial fibrillation ablation, pulmonary vein isolation by catheter for standard clinical indications~Exclusion Criteria:~* allergy or contraindication to adenosine,~* inability to give informed consent,~* currently taking dipyridamole,~* verapamil or theophylline and~* breast-feeding mothers.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Adenosine arm (Type: EXPERIMENTAL): 25 patients will be randomized to received 2 doses of adenosine 12 mg IV, 5 minutes apart after pulmonary vein isolation. During this time, will monitor for pulmonary vein reconnection, second dose of adenosine will be given only if no reconnection after initial dose.
- Observation arm (Type: NO_INTERVENTION): 25 patients will be randomized to 10 minute period of observation for pulmonary vein reconnection after documentation of pulmonary vein isolation. This will serve as the control arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).